argenx SE (NASDAQ:ARGX) Holdings Raised by Quantinno Capital Management LP

Quantinno Capital Management LP raised its holdings in shares of argenx SE (NASDAQ:ARGX - Free Report) by 34.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,386 shares of the company's stock after purchasing an additional 862 shares during the quarter. Quantinno Capital Management LP's holdings in argenx were worth $2,082,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. GeoWealth Management LLC boosted its stake in shares of argenx by 56.3% during the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company's stock valued at $31,000 after buying an additional 18 shares during the last quarter. Steward Partners Investment Advisory LLC raised its holdings in argenx by 5.6% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 380 shares of the company's stock valued at $234,000 after acquiring an additional 20 shares in the last quarter. SG Americas Securities LLC boosted its stake in argenx by 6.2% during the 4th quarter. SG Americas Securities LLC now owns 358 shares of the company's stock valued at $220,000 after acquiring an additional 21 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in argenx by 38.2% during the 4th quarter. Farther Finance Advisors LLC now owns 76 shares of the company's stock worth $47,000 after acquiring an additional 21 shares in the last quarter. Finally, Dynasty Wealth Management LLC grew its holdings in argenx by 3.4% during the 4th quarter. Dynasty Wealth Management LLC now owns 677 shares of the company's stock worth $416,000 after acquiring an additional 22 shares in the last quarter. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

argenx Trading Up 0.1%

argenx stock traded up $0.45 during midday trading on Tuesday, reaching $588.06. 77,303 shares of the stock traded hands, compared to its average volume of 324,544. argenx SE has a fifty-two week low of $359.37 and a fifty-two week high of $678.21. The firm has a market cap of $35.91 billion, a price-to-earnings ratio of -667.52 and a beta of 0.57. The firm has a fifty day moving average price of $589.13 and a two-hundred day moving average price of $613.08.

argenx (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.32 by $0.26. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The business had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $748.34 million. Analysts anticipate that argenx SE will post 3.13 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have recently commented on ARGX. Guggenheim reduced their price target on shares of argenx from $1,100.00 to $1,065.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. HC Wainwright restated a "buy" rating and set a $720.00 price objective on shares of argenx in a research note on Tuesday, April 8th. William Blair reiterated an "outperform" rating on shares of argenx in a research report on Friday, February 28th. Baird R W upgraded argenx from a "hold" rating to a "strong-buy" rating in a report on Tuesday, May 13th. Finally, Robert W. Baird raised argenx from a "neutral" rating to an "outperform" rating and set a $680.00 price target on the stock in a research report on Tuesday, May 13th. One investment analyst has rated the stock with a hold rating, twenty have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, argenx presently has a consensus rating of "Buy" and an average price target of $698.11.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.